Suppr超能文献

肉毒杆菌毒素治疗眼睑痉挛的健康相关生活质量结果。

Health-related quality of life outcomes from botulinumtoxin treatment in blepharospasm.

作者信息

Weiss Daniel, Hieber Leonhard, Sturm Justine, Börtlein Axel, Buchthal Joachim, Dippon Christian, Arnold Guy, Wächter Tobias

机构信息

Hertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Tübingen, Germany; Department of Neurodegenerative Diseases, Centre of Neurology, University of Tübingen, Tübingen, Germany.

Neurologische Klinik, Klinikum Stuttgart, Stuttgart, Germany.

出版信息

Clin Neurol Neurosurg. 2018 Sep;172:130-133. doi: 10.1016/j.clineuro.2018.06.040. Epub 2018 Jul 2.

Abstract

OBJECTIVE

Blepharospasm associates with impairment in generic health-related quality of life (HR-QoL). Albeit botulinum toxin is widely used to alleviate the motor symptoms of blepharospasm, its effect on generic health-related quality of life (HR-QoL) is heterogeneous.

PATIENTS AND METHODS

In this open-label clinical observational study, we characterized outcomes on HR-QoL in terms of the EuroQol (EQ-5D-5 L) from botulinum toxin (BoNT) injection in a prospective cohort of patients with blepharospasm (n = 55). Additionally, we characterized motor and non-motor signs of blepharospasm including motor symptom improvement, life satisfaction, depressive symptoms, pain and sleep quality. Patients were assessed at the end of a regular three-month period from last injection (Timepoint1) and four weeks after the re-injection of BoNT (Timepoint2).

RESULTS

There was no improvement of generic HR-QoL on group-level. Individual findings were heterogeneous, dividing patients in three groups of responders (RESP), unchanged outcomes (UNCHN), and worsening (WORSE). We identified, that these subgroups differed at Timepoint 1 with respect to EQ-5D-5 L, EQ-VAS, life satisfaction (health and movement disorders domains), Beck's Depression inventory, and sleep quality (One-way ANOVAs, P <  0.05, adjusted for multiple comparisons). In post-hoc Tuckey tests, RESP or WORSE showed distinct differences from UNCHN that might help to separate the subgroups in future. As such, RESP showed higher impairment in EQ-5D-5L, EQ-VAS, and Beck's Depression Inventory compared to UNCHN (unlike WORSE), whereas WORSE showed higher impairment in life satisfaction 'movement disorders' domain (unlike RESP).

CONCLUSION

Our study suggests, that several dependent non-motor, life satisfaction and generic HR-QoL measures associate to individual patient outcomes. The variables identified in this study may be validated in future studies to predict HR-QoL outcomes in patients with blepharospasm.

摘要

目的

睑痉挛与总体健康相关生活质量(HR-QoL)受损相关。尽管肉毒杆菌毒素被广泛用于缓解睑痉挛的运动症状,但其对总体健康相关生活质量(HR-QoL)的影响并不一致。

患者与方法

在这项开放标签的临床观察研究中,我们以前瞻性队列研究的方式,对55例睑痉挛患者注射肉毒杆菌毒素(BoNT)后的总体健康相关生活质量(HR-QoL)进行了欧洲五维健康量表(EQ-5D-5L)评估。此外,我们还对睑痉挛的运动和非运动体征进行了评估,包括运动症状改善情况、生活满意度、抑郁症状、疼痛和睡眠质量。患者在最后一次注射后的常规三个月末(时间点1)和再次注射BoNT四周后(时间点2)接受评估。

结果

在组水平上,总体健康相关生活质量没有改善。个体结果存在异质性,患者被分为三组:反应者(RESP)、结果未改变者(UNCHN)和恶化者(WORSE)。我们发现,这些亚组在时间点1时在EQ-5D-5L量表、EQ视觉模拟量表(EQ-VAS)、生活满意度(健康和运动障碍领域)、贝克抑郁量表以及睡眠质量方面存在差异(单因素方差分析,P<0.05,经多重比较校正)。在事后的Tukey检验中,反应者组(RESP)或恶化者组(WORSE)与结果未改变者组(UNCHN)存在明显差异,这可能有助于在未来区分这些亚组。具体而言,与结果未改变者组(UNCHN)相比(与恶化者组不同),反应者组(RESP)在EQ-5D-5L量表、EQ-VAS量表和贝克抑郁量表上的受损程度更高,而恶化者组(WORSE)在生活满意度“运动障碍”领域的受损程度更高(与反应者组不同)。

结论

我们的研究表明,一些相关的非运动、生活满意度和总体健康相关生活质量指标与个体患者的结果相关。本研究中确定的变量可能在未来的研究中得到验证,以预测睑痉挛患者的健康相关生活质量结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验